Last reviewed · How we verify
KCP-330
At a glance
| Generic name | KCP-330 |
|---|---|
| Also known as | Selinexor |
| Sponsor | Karyopharm Therapeutics Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Fatigue
- Nausea
- Diarrhoea
- Constipation
- Vomiting
- Dyspnoea
- Decreased appetite
- Hyponatraemia
- Anaemia
- Oedema peripheral
- Hypomagnesaemia
- Dysgeusia
Key clinical trials
- Selinexor and Backbone Treatments of Multiple Myeloma Patients (PHASE1, PHASE2)
- A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (PHASE2, PHASE3)
- A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma (PHASE1)
- Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma (PHASE2)
- Selinexor in Advanced Liposarcoma (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KCP-330 CI brief — competitive landscape report
- KCP-330 updates RSS · CI watch RSS
- Karyopharm Therapeutics Inc portfolio CI